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Abstract:  Stimulus-responsive drug-loaded poly (N-isopropylacrylamide) nanogels 
were examined as a means of enhancing the delivery of naproxen into skin ex vivo. 
Following massaging into skin, the epidermis was probed (with and without base 
activation) for depth penetration and transdermal delivery of drug, and anti-
inflammatory activity in the relative levels of COX-2 expression. Rat paw oedema 
testing was used to determine anti-inflammatory effects in vivo. When activated by 
sodium carbonate, particle size reduced by 19%. Tape stripping revealed significantly 
greater delivery of naproxen into the epidermis for the activated nanogel and the 
steady state flux was enhanced 2.8-fold. With base-activation COX-2 was 50% lower 
than non-activated, and this trend was confirmed by immunostaining, and by the 
reduction of rat paw swelling which provided ex vivo – in vivo corroboration. A 
mechanism of action is proposed. In conclusion, stimulus-responsive nanogels have 
potential for enhancing dermal drug delivery and therapeutic outcomes in 
inflammatory skin diseases. 	
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Background	
Nanoparticles are widely evaluated in novel drug delivery systems.1-3 Nanogels are 
sub-micron swollen nanoparticles composed of a hydrogel – a crosslinked hydrophilic 
network of synthetic polymers or biopolymers.4	Nanogels undergo abrupt, reversible 
changes in volume in response to minor changes in the environment, such as 
temperature, pH, ionic strength, electric field, light intensity, as well as specific 
chemical stimuli.5,6 Polymers based upon N-isopropylacrylamide (PNIPAM) have 
been widely used to prepare temperature-responsive hydrogels which possess a range 
of interesting physicochemical properties: low viscosity, very high surface area, pH 
and rapid thermal sensitivities. Such properties give them potential in ‘smart’, 
‘controlled’ and ‘regulated’ drug delivery applications. For example, below the 
critical solution temperature (LCST) of approximately 32 °C, PNIPAM swells in 
water and imbibes any dissolved solute (drug); whereas above the temperature the 
structure collapses expelling water and solute, a process assisted by a decrease in 
internal hydrophilic environment.7 Changes in pH cause a similar response. 
Skin inflammation, erythema and pain is generally mediated by an 
upregulation in the local production of eicosanoids, in particular the prostaglandin 
PGE-2, which is biosynthesized by the action of cycloxygenase-2 (COX-2) – the 
target for anti-inflammatory drugs, including non-steroidal anti-inflammatory drugs 
(NSAIDs) and selective COX-2 inhibitors.8 Topical delivery, where appropriate, 
allows for localised and reduced doses, and also avoids the potential for 
gastrointestinal irritation. However, the skin has evolved to be an efficient barrier to 
the ingress of xenobiotics including NSAIDs and this causes difficulties for the 
development of efficacious transdermal and local, targeted dermatologically active 
drug delivery systems.  Numerous strategies have been employed to overcome the 
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barrier including microneedles.9 The use of nanogels for topical applications has been 
studied previously10,11 for the delivery of estradiol, minoxidil and caffeine.2,12,13 The 
size and release properties of nanogels are the essential key when designing nanogel 
delivery systems, and the sharp phase transition or lower critical solution temperature 
of PNIPAM nanogels in aqueous solution, approximately 32 °C, is highly appropriate 
as the average skin surface temperature is 32-34 °C and has been shown to provide 
stimulus-responsive enhanced topical drug delivery of and caffeine and 
methotrexate.13,14 Topical naproxen gels have been reported with limited success.15 
Lipid nanoparticles have recently been previously reported for the delivery of 
naproxen into skin, although no evidence was provided to demonstrate anti-
inflammatory effect.16  
The aim of the present study was to evaluate environmental modulation on the 
ability of responsive PNIPAM nanogels to deliver naproxen into and across the skin 
and assess consequent biological effects in the keratinocytes of the viable epidermis, 
ex vivo in the modulation of epidermal COX-2 ex vivo17,18 and verification of the 
effect in vivo using the rat paw oedema model.19 
	
Methods	
Materials 
Naproxen was obtained from Abdi Ibrahim Pharm (Istanbul, Turkey). N-
isopropylacrylamide 97% (NIPAM), butyl acrylate 99% (BA), N,N-
methylenebisacrylamide 99% (BIS), potassium persulphate 99.9%, citric acid (CA), 
sodium carbonate (SC), Radioimmunoprecipitation assay buffer (RIPA buffer, 
comprised of 50 mM tris-HCl (pH 7.4), 1 mM EDTA,1% Triton X-100, 1% sodium 
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deoxycholate, 150 mM NaCl, 0.1% SDS, 1 mM phenylmethylsulfonyl fluoride serine 
protease inhibitor), Hanks balanced salt solution (HBSS), gentamycin sulphate, 
Ponseau S, PBS + 0.05% TWEEN, aprotinin, leupeptin, anti-actin antibody, sodium 
azide, SDS 10%, paraffin wax pellets, phosphate buffer saline pH 7.4 (PBS), methyl 
green, distyrene/plasticizer/xylene (DPX mountant) and λ-carrageenan were all 
purchased from Sigma-Aldrich, Poole, UK. Trifluoroacetic acid, triethylamine and 
HPLC-grade solvents were purchased from Fisher Scientific (Loughborough, UK). 
Primary COX-2 antibody (#4842) was purchased from Cell Signalling Technology 
(Boston, USA). Horseradish peroxidase (HRP)-labelled anti-rabbit polymer, DAB 
chromagen plus substrate was from Dako UK (Ely, England). Western blocking 
reagent was from Roche Diagnostics, Gmbh (Mannheim, Germany). Rainbow Marker 
(10-250 Kd), anti-mouse HRP, (HRP)-linked antibody were from Amersham 
Biosciences Ltd (Buckinghamshire, UK). Dura substrate was from Perbio, 
Cramlington, UK, and 3,3'-Diaminobenzidine (DAB) chromagen-AB substrate was 
from Abcam, Cambridge, UK. Freshly excised porcine ears were obtained from a 
local abattoir prior to steam cleaning, immediately following slaughter. 
 
Synthesis of Naproxen-loaded PNIPAM Nanogels 
PNIPAM nanogels were prepared by surfactant-free emulsion polymerisation in 
deionised water at 60 ºC, under nitrogen. For the blank nanogel (BN), potassium 
persulphate was dissolved in 200 mL deionised water in a 500 mL, three-necked 
round-bottomed flask and stirred continuously at 120 rpm. NIPAM (2g) and BA (0.25 
mL) as co-monomers, and N,N-methylenebisacrylamide (7.5%) as the crosslinker 
were dissolved in 200 mL deionised water and mixed with the potassium persulfate 
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under stirring and then added to the reaction vessel. After 6 h the crosslinked 
PNIPAM nanogels were cooled to room temperature and purified by multiple 
washing/centrifugation /washing at 50,000 x g, 20°C for 1 h in an Avanti® J-25 
centrifuge (Beckman, Fullerton, CA), with distilled water, until the conductivity was 
less than 1 µS cm−1.20 For NN, 500mg naproxen was dissolved in the potassium 
persulfate solution beforehand with a pH of 6, whereas for NNCA the potassium 
persulfate solution containing naproxen was also adjusted to pH 2.5 with citric acid 
prior to mixing base (Table 1). 
Particle diameter and size distribution of the purified nanogel particles were 
determined by a laser diffraction system, Malvern Mastersizer 2000 (Malvern 
Instruments Ltd., Malvern, UK). Drug-loaded nanogel suspension was ultra-
centrifuged at 150000 × g (Beckman Coulter J25), for 2 hours to separate the free 
drug from encapsulated drug. The clear supernatant above the nanogels was removed 
by decanting before being assayed for dissolved naproxen by HPLC. The 
reproducible product - a viscous precipitate - was used for further experimentation. 
Confocal images were determined by scanning laser microscopy (CSLM, MRC 1024 
UV, Bio-Rad, Hemel Hempstead, UK) using a 60 × water immersion lens (Nikon, 
Badhoevedorp, Netherlands).  
 
Percutaneous penetration 
Freshly excised porcine ear skin was liberated from the underlying cartilage by blunt 
dissection, whilst being continually bathed in Hanks buffer and 2 x 2 cm2 membranes 
were mounted on the pre-greased flanges of all-glass Franz-type diffusion cells9, with 
nominal diffusional diameter of 1 cm and receptor phase volume of 3 mL, which was 
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degassed Hanks buffered salt solution (HBSS)-gentamycin. Receptor compartments 
were filled with degassed Hanks buffer, and micro stirrers added. The complete 
assemblies were placed on a submersible stirrer plate in a water bath set at 37°C. 
After equilibration for 15 min the skin was dosed using the flattened end of a glass 
rod to gently massage 200mg of the viscous nanogel slurry onto the skin using 10 
rotations. An equimolar naproxen solution comparator was prepared at pH6. In the 
case of the ‘activated’ samples, an aliquot of either 100 µL of 0.1M sodium carbonate 
(or triethylamine for Western blotting) was added and massaged by a further 10 
rotations (NNCA+SC and NNCA+TEA). When required, the cells were dismantled 
and the skin membranes recovered. 
 
Tape stripping  
Tape stripping is a commonly used technique for the comparative assessment of 
xenobiotic penetration into skin.9 Regular Sellotape strips, approximately 25mm in 
length, were pressed onto the pig ear skin and then removed using forceps, before 
being placed into clean glass vials containing 2 mL methanol. This was repeated 10 
times before methanol (2 mL) and the vials left for 24 h on a shaker (Infors HT 
Labotron, Germany) at room temperature. Tapes were removed and the solutions 
added to HPLC vials. The remaining skin of the diffused area was excised, cut into 
small pieces and also extracted with methanol. The drug amounts in the first strips 
were not included in the analysis to eliminate any possible surface contamination. 
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HPLC Analysis 
Naproxen was determined using an Agilent 1100 automated HPLC system with a 
Phenomenex Kingsorb C18 column (150 x 4.6 mm, 5 µm). The mobile phase was 
acetonitrile/water (adjusted to pH 2.5 with trifluoroacetic acid) (60:40 v/v) run 
isocratically at a flow rate of 1.0 mL min-1. UV detection was at 271 nm and the 
retention time of naproxen was 7.8 min.  
  
Western blotting analysis of COX-2  
Semi-quantitative modulation of COX-2 in skin as a consequence of dosing with 
nanogels was determined by Western blotting.21,22 After 6 or 10h skin samples were 
recovered from the diffusion cells, gently cleansed with de-ionized water before being 
homogenized (Silverson, Chesham, UK) in as RIPA lysis buffer plus an additional 5 
µg mL-1 of the protease inhibitors aprotinin and leupeptin. After 15 min incubation on 
ice, the lysates were centrifuged at 14000 x g for 2 x 15min and the supernatant stored 
at -80 ˚C until required.  
The protein content of the lysates was determined using the Biorad D/C 
protein assay kit (Bio-Rad Laboratories, Hercules, CA). Aliquots of 30 µg proteins 
with one channel for the Rainbow marker were separated by SDS-PAGE, transferred 
to nitrocelullose membranes using the Trans-Blot electrophoretic Transfer Cell (Bio-
Rad Laboratories, Hercules, CA), and briefly stained with Ponceau S to verify 
effective transfer. Immunoblots were incubated for 1 h in the blocking solution 
containing 5% (w/v) commercial Marvel milk powder (Premier Foods, St Albans, 
UK) at room temperature. After washing, the membrane was probed overnight at 4 ˚C 
with COX-2 antibody at 1:1000 in (1:20 and 1:100 western blocking reagent (Roche) 
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and sodium azide respectively made up to volume with TBS tween). Membranes were 
then incubated for 1 h with HRP-conjugated anti-rabbit. For β-actin, membranes were 
probed with mouse anti-actin antibody and anti-mouse (Neomarkers Ab-10) for 1 h 
each at room temperature. After 3x10 min washes in TBS Tween, they were exposed 
to freshly prepared Dura Substrate for chemiluminescence for 20 min before 
performing autoradiography.18 
 
IHC analysis of COX-2 expression  
Visualisation of relative COX-2 levels in situ were determined based on a previously 
reported method17,18 skin samples were cut into 5 x 2 mm sections after 3, 6, and 10 h 
(n = 3) and placed in 4% formaldehyde then left to fix for 24 h. The skin was 
immersed sequentially in 70% to 90% to 100% ethanol solutions to displace all the 
water from the tissue, then into four chloroform baths to displace the alcohol. The 
skin sections were subjected to immersion in a series of three molten wax baths 
attached to a vacuum to eliminate the remaining chloroform, before being embedded 
in a paraffin wax block. The skin was then cut using a Shandon Finesse microtome 
and sections were transferred onto pre-cleaned regular micro-slides (Surgipath, 
Peterborough, UK). After re-hydration with ethanol and equilibration in PBS, 
specimens were blocked with PBS Tween for 15 min. The COX-2 primary antibody 
was then applied diluted 1:50 in PBS and stored overnight at 25 ºC in a humidified 
chamber. The slides were then washed with PBS for 2 x 5 min and incubated in HRP 
labelled anti-rabbit for 2 h at 25 ºC. Slides were washed in PBS for three min 
followed by 2 x 5 min washes in PBS/Tween. An aliquot (0.75 µL) of visualization 
solution (DAB chromagen-AB substrate) was applied for 10 min. Following another 
washing in deionised H2O, the slides were counter-stained with 0.5% methyl green 
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for 3 min. Finally, sections were rinsed in distilled water and dried in an oven at 40 
ºC. DPX mountant was used to cover slips ready for microscope analysis.  
 
In vivo rat paw oedema 
The carrageenan-induced inflammation in the rat paw model of oedema formation and 
hyperalgesia19 was used to examine the in vivo effects of the nanogel formulations in 
male albino Wistar rats weighing 180–220 g. The experimental protocol was 
approved by the Local Ethics Committee for Animal Experiments, Ege University, 
Turkey, approved project number 2009-3. The animals were housed in standard 
environmental conditions and fed with standard rodent diet with water ad libitum, and 
all procedures were carried out in accordance with the institution's animal subject 
review committee. Inflammation was introduced in rats under anesthesia by using 
100 µL of a 1% (w/v) λ-carrageenan solution in saline. The solution was injected into 
the plantar surface of the left hind paw of the rats and the contra-lateral paw received 
the same volume of sterile saline solution. To evaluate the topical anti-inflammatory 
activity of the formulations, three groups of animals (n = 6) with carrageenan-induced 
paw oedema were examined. An initial group of rats was used as a control 
(untreated), and they received only the carrageenan solution. Formulations were 
applied to the plantar surface (0.125 mg/cm2) of the hind paw of the rats by gentle 
rubbing with the formulation 50 times with the index finger for each treatment, 1 hour 
before induction of inflammation. The increase in paw volume (oo) was measured 
using calipers at 0, 1, 2, 3, 4, 5 and 6 h after carrageenan administration. The percent 
inhibition of oedema induced by carrageenan was calculated for each group using the 
following equation: 
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% swelling =  Vcontrol – Vtreated/Vcontrol x 100 
 
Data Analysis and Statistics 
Statistical analysis was performed using an ANOVA and Kruskal Wallis non-
parametric post-tests using Instat for Macintosh (GraphPad Software Inc, La Jolla, 
CA, USA) 
 
Results 
Nanogel synthesis 
Naproxen microgels were successfully synthesized, and mean hydrodynamic diameter 
for the blank nanogel (BN) particles was found to be 327 ± 16.9 nm and statistically 
the same as naproxen nanogel (NN) which was 311 ± 14.1 nm. The nanogel adjusted 
with citric acid to pH 2.5 (NNCA) had larger particle size at 356 ± 16.8. Treatment of 
NNCA with sodium carbonate (NNCA+SC) resulted in a statistically significant 
reduction in particle size to 289 ± 12.1 nm (p<0.05). Representative confocal 
microscopy and TEM images are shown in Figure 1 which also showed that the 
nanogels exhibited good monodisperse spheres with regular size. Polydispersity 
measurements show the lowest value for the blank nanogel (BN), with the highest for 
NNCA+SC. 
 
 
 
    
	 	 12	
Transdermal delivery 
Control BN confirmed there was no naproxen, or co-eluting compound, present in the 
receptor phases.  For the naproxen nanogel prepared under ‘standard’ conditions (pH 
6), NN, the Jss was 15.38 ± 1.67 µg cm
-2 h-1; this was 2.5x greater than the control 
equimolar naproxen solution at pH 6, for which the flux was 5.3 ± 1.1 µg cm-2 h-1. For 
NNCA, Jss was slightly lower at 12.93 ± 2.85 µg cm
-2 h-1 although this difference was 
not statistically significant. However, for NNCA+SC there was a 2.8-fold increase in 
Jss at 42.83 ± 3.95 µg cm
-2 h-1 which was statistically different, p <0.05, compared to 
both NN and NNCA (Table 1).  Acidified solution was not examined because of the 
low aqueous solubility of the free acid at pH 2.5 (2% ionisation, as pKa = 4.15). 
Basified naproxen solution was not examined as this would result in 98.6% ionization 
of the drug, which is known to result much-reduced flux across skin relative to the 
free-acid form. 
 
Tape stripping 
Figure 2 shows depth profiles for naproxen using 7.5% cross linker, following the 
application to porcine ear skin of three test nanogels and naproxen solution. Naproxen 
was delivered throughout the skin, although significant differences were found 
between the different nanogels.  The nanogel formulation NNCA, followed by SC 
provided the greatest delivery across all strippings and remaining skin; this was 
statistically significant in all cases (p<0.05). The nanogel formulation NN (prepared at 
pH 6) was next highest, and the delivery of naproxen from nanogel NNCA, prepared 
in the presence of citric acid (pH 2.5), was generally lower. The lowest delivery was 
from the aqueous solution of naproxen. The rank order was: NNCA+SC > NN  = 
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NNCA+TEA> NNCA > naproxen solution. Summation of naproxen in the strips 
shows total drug delivered: NNCA+SC 3175 mg, NN 2323 mg, NNCA 1750 mg, 
naproxen solution 790 mg (Table 1, Figure 3). These figures followed the same trend 
as for the transdermal delivery. 
 
Western Blotting 
Representative Western blots for COX-2 expression in porcine skin dosed with 
naproxen-loaded nanogels or naproxen solution, are shown in Figure 4.  The trend 
after both 6h and 10h was: Control > naproxen solution > NNCA > NNCA+TEA > 
NNCA+CA. NNCA (prepared under acidic conditions with citric acid) elicited a 
greater effect than the equivalent solution, indicating superior delivery. When the 
applied dose was activated with TEA there was no increase in COX-2 expression. 
However, when activated by sodium carbonate there was a marked reduction in COX-
2 level. The trends are further illustrated in Figure 5. 
 
Immunostaining  
Figure 6 shows immunostaining images for the presence of COX-2, where higher 
presence of COX-2 is visualized as darker staining and lower presence is seen as 
lighter staining allowing comparative semi-quantitative analysis. After 6 h, the control 
samples showed the highest levels of COX-2, NNCA was lower, while the activated 
nanogel NNCA+SC showed the lowest COX-2. The same trend was apparent at 10h, 
although the NNCA nanogel showed almost as much COX-2 as the control. These 
trends that support that observed in the Western blotting data. 
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Rat paw oedema 
Carrageenan-induced oedema of the paw causes an up-regulation of COX-2 and an 
increase in prostanoids19 resulting in tissue swelling (Figure 7). A plot of  % swelling 
versus time, post carrageenan administration and following application of the 
nanogels is shown in Figure 7, with maximal swelling after 3h. The blank nanogel 
control showed generally higher swelling than the naproxen solution control, although 
not statistically significant. NNCA (naproxen nanogel with citric acid) produced 
generally lower swelling which was statistically lower than controls at 3h. For the 
naproxen nanogel with citric acid, then sodium carbonate (NNCA+SC) the swelling 
lower and statistically significant at 3 and 4h relative to controls. Single-dose 
administration of naproxen (15 mg/kg) or indomethacin (10 mg/kg) was found to 
decrease in rat paw oedema volume within 5 h after oedema induction by 
carrageenan23 thus the nanogels in the current work appear to have more rapid onset 
of action. 
 
Discussion 
PNIPAM gels are known to de-swell with increased temperature and pH, thus 
two simultaneous environmentally responsive mechanistic factors were in play. 
Firstly, PNIPAM has temperature-sensitive phase behavior in water, with a lower 
critical solution temperature (LCST) at about 32 °C – the average surface temperature 
of skin. Below this temperature, PNIPAM is hydrophilic and swells in water, while 
above the temperature, it collapses into a smaller volume and becomes less 
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hydrophilic as hydrophobic groups are in contact with both water and polymer 
segments facilitating expulsion of water and drug solubilised therein.7 However, the 
data for NNCA nanogels were inferior to those for NNCA activated with sodium 
carbonate, NNCA+SC. Therefore, temperature responsiveness does not fully account 
for the observed data, rather, the change in pH appeared to be more important. In 
terms of the second factor, it is known that PNIPAM gels de-swell with increased pH 
and Table 1 shows that addition of SC resulted in a collapse of ~19% - figure that 
agrees well with the 19.9% reported previously.13 
Preparing the nanogels under acidic conditions ensured two things – firstly 
that the nanoparticle structures would be formed in their expanded form and secondly, 
that the entrapped naproxen was in the free-acid form, rather than ionic, which would 
both inhibit drug leaching into an aqueous environment. When the drug-loaded 
nanogel was massaged into the skin it would have commenced the penetration 
process. Subsequent addition of base (sodium carbonate or triethylamine) would have 
resulted in a pH increase in the local environment of the particles which, assisted by 
the elevation in temperature from ambient (21 °C) to that of the skin surface (32 °C), 
instigated nanoparticle de-swelling in situ. Thus, a volume equating to ~20% of the 
absorbed water/drug load would have been released or dumped within the skin in 
response to such changes in the nanogel structure.  
The dose dumping of naproxen could have occurred within the stratum 
corneum, boosting the drug reservoir hence thermodynamic activity within this tissue 
which, from Fick’s first law, would be expected to enhance the delivery rate into the 
viable epidermis. Alternatively, dumping may have occurred within the viable 
epidermis, given rapid penetration from the dose massaged in to the skin surface 
which, being unionized, would also maximize the penetrability of released naproxen 
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of the lipophilic domains of the keratinocyte membranes; in the skin, COX-2 is 
expressed predominantly in suprabasal keratinocytes. 24 However, it is recognized that 
an unknown amount of naproxen may ionize under such conditions. Either of these 
processes, or more likely a combination of the two at the same time, resulted in 
significantly higher levels of naproxen being delivered into the skin. This is evidenced 
in the fact that tape stripping data, which relates to mass transfer of transfer, reflected 
the COX-2 and in vivo data well, specifically: the greater the mass transfer of 
naproxen into the viable epidermis, the greater the greater the anti-inflammatory 
activity by downregulation of COX-2 expression. 
Recently porcine skin is a generally accepted as a model for human skin25,26  
and has been used previously as a model to demonstrate anti- and pro-inflammatory 
effects of a range of topically applied xenobiotics including the steroidal anti-
inflammatory drug betamethsone dipropionate and another NSAID, ibuprofen.18,22 
COX-2 is a constitutive enzyme which is upregulated in inflamed tissue where its 
function is to produce eicosanoids from arachidonic acid in response to the 
inflammatory stimulus. COX-2 has a short lifespan of 1-2 min at Vmax after which it 
resolves, becoming permanently inactivated after converting several hundred 
arachidonic acid molecules to prostaglandins.27 When the inflammatory stimulus 
diminishes or in the presence of an anti-inflammatory agent acting at some stage in 
the cascade28, the levels of eicosanoids reduce, causing downregulation in the 
expression of COX-2. Blockade of COX-2 not only inhibits formation of 
prostaglandins, leading to reduced pain and inflammation and erythema, it also results 
in lower COX-2 regulation by feedback. 
Thus the data clearly indicate the presence of higher bioavailability of 
naproxen delivered from the activated nanogel resulting in the downregulation of 
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COX-2 expression, as observed using both Western blotting and immunostaining. 
Ideally, confirmatory data on the effect on prostaglandin biosynthesis, particularly 
pro-inflammatory PGE2, would have been useful; however, propionic acid-based 
‘profen’ COX inhibitors, including naproxen, are well known to have this effect. 
Inflammation is a complex physiological response and it would have been interesting 
to examine the effects of enhanced naproxen skin penetration on lipoxygenase activity 
and pro-inflammatory TNF-α, IL-1β and IL-6; however, the major pharmacological 
action of naproxen is as a COX-2 inhibitor so such cytokines would be of lesser 
relevance. 
The widely-used rat paw oedema model provided confirmatory evidence of 
the percutaneous penetration and COX-2 modulation data in an in vivo system – this 
is in line with other work that has also demonstrated in vitro an in vivo relationships 
using this technique.29  Indirectly, the data also support the biocompatibility of the 
PNIPAM nanoparticles, and this was explored previously using the COX-2 where no 
adverse effects were indicated.30  
The issue of nanoparticle delivery into skin is contentious, with conflicting 
reports on the ability of such entities to penetrate beyond the stratum corneum.31 
However, we were able to detect PNIPAM nanogels in the receptor phases of Franz 
diffusion cells9 having passed through the entire skin membrane; moreover, the 
topical naproxen delivery and biological COX-2 modulation data presented here can 
only be explained by the delivery of naproxen to the viable epidermis, with enhanced 
COX-2 downregulation being a consequence of nanogel particle penetration into the 
skin.13,30 We have observed similar results previously using activated nanogels.14  In 
this work, the nanogel was massaged into skin where commenced the penetration 
process.  
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Conclusions Nanotechnology has recognised potential in the management of 
treating inflammatory disorders.32 Overall, the current work suggests not only that 
naproxen-loaded PNIPAM nanogels can target inflamed skin, but also that enhanced 
biological activity ensues in terms of anti-inflammatory activity, both ex vivo and in 
vivo following response to environmental stimuli. The system has potential clinical 
relevance where rapid onset of anti-inflammatory activity is desirable in skin, eg 
eczema, mild burns, sunburn or other inflammatory conditions such as periodontitis.  
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Table 1 PNIPAM nanogel preparation and percutaneous penetration parameters (n=3) 
Abbreviation Nanogel preparation Particle size 
nm 
Poly- 
dispersity 
Total naproxen 
skin content 
µg cm
-2
  
Naproxen Jss  
µg cm
-2
 h
-1
 
Nap sol Naproxen solution (pH 6)  - - 990 ± 167 5.3 ± 1.1 
BN Blank nanogel (pH 6) 
 
327 ± 16.9 0.106 ± 0.04 0 0 
NN Naproxen nanogel (pH 6) 311 ± 14.1 0.133 ± 0.01 2323 ± 646 15.38 ± 1.67  
NNCA Naproxen nanogel (pH 2.5), no activation 356 ± 16.8 0.124 ± 0.04 1750 ± 222 
	 	
12.93 ± 2.85  
NNCA+SC Naproxen nanogel (pH 2.5), sodium carbonate activation 289 ± 12.1 0.172 ± 0.06 3175 ± 343 42.83 ± 3.95 
Notes: Nanogel solution, equimolar with NNCA content; blank nanogel made at pH6; naproxen nanogel is a loaded nanogel following 
addition of naproxen to reaction mixture.   NNCA: naproxen nanogel adjusted to pH 2.5 with citric acid; NNCA+SC: naproxen nanogel 
adjusted with citric acid to pH 2.5, then activated with 100 µL 0.1M sodium carbonate. 
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Figures 
 
Figure 1 Images showing PNIPAM nanogels.  
Notes: A. Confocal microscopy images of naproxen-loaded nanogel prepared at pH 
6.0, and B. adjusted with citric acid pH 2.5, B (bar = 500nm) showing size decrease 
due to pH change. C. TEM image of blank nanogel particles (bar = 500nm). 
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Figure 2 Depth profiles for the delivery of naproxen into porcine skin from three 
PNIPAM nanogels and solution of naproxen, 10 strips and remaining skin (µg/cm
2
 
versus relative skin depth).  
Notes: Left to right in each cluster of four: naproxen nanogel with citric acid + 
sodium carbonate (NNCA+SC) blue, naproxen nanogel (NN) red, naproxen nanogel 
with citric acid (NNCA) green, naproxen solution, yellow (mean ± SD, n=3).  
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Figure 3 Total naproxen delivered into skin from the applied formulations (µg/cm
2
). 
Notes: Summation shows total naproxen per square centimetre: NNCA+SC 3175 mg, 
NN 2323 mg, NNCA 1750 mg, naproxen solution 790 mg. 
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Figure 4 Representative Western blots for COX-2 expression following the dosing of 
porcine skin with naproxen-loaded PNIPAM nanogels after 6 and 10h, relative to 
water control.   
Notes: The upper blots show COX-2 for each treatment where the intensity of the 
bands and is directly proportional to protein level. The lower blots show the β-actin 
control. The histogram shows relative COX-2 levels as a percentage of the control 
(mean ± SD, n=3) * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 
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Figure 5 Plot showing % COX-2 Western blotting trends at 6h (blue) and 10 (red): 
Control > naproxen solution > NNCA ≈ NNCA+TEA > NNCA+SC. 
Notes: Trend shows: control > naproxen solution > NNCA ≈ NNCA+TEA > NNCA 
+ CA. NB: the lower the COX-2 the greater the anti-inflammatory effect. 
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Figure 6 Representative immunostaining images for COX-2 for ex vivo porcine skin 
dosed with PNIPAM nanogels. 
Notes: Ex vivo porcine skin treated with: A. Blank nanogel after 6h, B. Blank nanogel 
after 10h, C. naproxen nanogel with citric acid after 6h, D. naproxen nanogel with 
citric acid after 10h, E. naproxen nanogel with citric acid, then sodium carbonate after 
6h, F. naproxen nanogel with citric acid then sodium carbonate after 10h. 
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Figure 7 Time course of carrageenan-induced oedema in the in vivo rat paw test 
following administration of PNIPAM nanogels.  
Notes: Results are expressed as % swelling determined at different times after 
injection of carrageenan in the left hind footpad. A. normal and swollen rat paws, B. 
application of formulation. C. paw swelling versus time, post carrageenan 
administration.  Green: naproxen solution control, Blue: blank nanogel control, Red: 
NNCA (naproxen nanogel with citric acid), Black: NNCA+SC (mean ± SD, n=3)  
	
